SWShohei Wakao

Shohei Wakao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shohei Wakao has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic Window for Intravenous Human Muse Cell Administration in Mouse Spinal Cord Injury

    by Kotaro Sakashita, Yoshihiro Kushida, Shohei Wakao, Hiroshi Takahashi, Yasuhiro Horibata, Shun Okuwaki, Yosuke Ogata, Takane Nakagawa, Takahiro Sunami, Hisanori Gamada, et al.

    Stage-specific embryonic antigen-3-positive pluripotent-like/macrophage-like multilineage-differentiating stress-enduring (Muse) cells are a distinct subpopulation of mesenchymal stromal cells (MSCs), accounting for 1% to several percent of MSCs. Although stem cell therapy for spinal cord injury (SCI) typically targets the subacute phase to avoid the hostile acute environment, the therapeutic window for Muse cells remains unclear. C57BL/6J mice with severe T9 contusion SCI received a single tail vein injection of human bone marrow-derived (BM) Muse cells, BM-MSCs (both 5 × 104 cells), or vehicle at 2, 8, 14, or 28 days post-injury (DPI) without immunosuppressants. Among the different administration time points, the 2-DPI Muse cell group exhibited significantly higher Basso Mouse Scale scores than the BM-MSC and vehicle groups from 14 days after injection, while no significant differences were observed at the other administration time points. The 2-DPI Muse cell group showed significantly greater homing to the injured spinal cord than the BM-MSC group, with persistent engraftment and neural-lineage marker expression at day 42. Ablation of engrafted Muse cells at day 42 partially reversed locomotor recovery, suggesting that engrafted Muse cells contributed to functional recovery. These findings suggest that intravenous Muse cell therapy exerts timing-dependent therapeutic effects after SCI, with greater efficacy during the early post-injury phase.


  • Open Access

    Muse cell known as a kind of Stem cell enabled therapy for SARS-CoV-2-Lung and Olfactory Impairment in Syrian Hamsters and may also have therapeutic effects for long COVID

    by Jun Fujii, Satoshi Shibata, Hiroshi Ito, Toshihiro Ito, Shohei Wakao, Hiroko Hagiwara, Kaori Yasuda, Naoya Ohara, Noriko Shibata, Toyoshi Yanagihara, et al.

    Background Long COVID, including symptoms such as asthma, allergies, musculoskeletal pain, diabetes, insomnia, headaches, chronic fatigue, and frailty persisting for at least 2 months following acute SARS-CoV-2 infection, is a global health concern with no established treatments. While some studies demonstrated efficacy using mesenchymal stem cells (MSCs), outcomes have been inconsistent. Methods In the present study, we evaluated a small, distinct subset of SSEA-3(+) MSCs, known as multilineage-differentiating stress-enduring (Muse) cells, in a preclinical model of SARS-CoV-2 infection. Here, in a Syrian hamster model of SARS-CoV-2 infection, Syrian hamsters were intranasally inoculated with SARS-CoV-2 on day 0, and then on day 2, the hamsters were intravenously administered Muse cells, non-Muse cells, or vehicle (saline). On day 8, the hamsters were sacrificed, and the lungs and olfactory bulb (OB) were removed from the body to perform the experiments including inflammatory response, apoptosis, fibrosis (lung only). At the same time, total RNA was extracted from the lung and OB for RNA-seq and IPA analysis. Results We demonstrated that intravenous treatment with human-bone marrow-derived Muse cells more effectively reduced inflammation, fibrosis, and apoptosis than non-Muse-MSCs while preserving oxygen saturation, body weight, lung and olfactory bulb structure, and alveolar air space. RNA sequencing identified 64 differentially expressed genes associated with Muse cell-mediated tissue protection, with distinct profiles in olfactory bulb and lung tissues. Although this study does not directly assess long COVID, the marked suppression of severe COVID-associated pathology suggests that Muse cell treatment holds promise as a potential therapeutic approach for long COVID. Conclusions Our findings demonstrated that Muse cells suppressed the expression of inflammatory, apoptosis, fibrosis mediators that may exacerbate severe COVID-19 pathology as ARDS. Some reports suggest that SARS-CoV-2 infection in the olfactory bulb provides a route for SARS-CoV-2 viral invasion of the brain, leading to neurologic symptoms of long COVID. Therefore, we propose that Muse cells could ameliorate both pulmonary and neurologic components of long COVID by suppressing key inflammatory and fibrotic pathways. Because Finally, these findings suggest that Muse cells may be a promising therapeutic approach for mitigating the symptoms of severe COVID-19 infection and preventing long COVID.